| Symbol | COLL |
|---|---|
| Name | COLLEGIUM PHARMACEUTICAL, INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA 02072 |
| Telephone | 781-713-3699 |
| Fax | — |
| — | |
| Website | https://www.collegiumpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001267565 |
| Description | Collegium Pharmaceutical Inc is a specialty pharmaceutical company. It is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol. Additional info from NASDAQ: |
New Form SCHEDULE 13G - COLLEGIUM PHARMACEUTICAL, INC <b>Filed:</b> 2026-07-31 <b>AccNo:</b> 0002100119-26-001318 <b>Size:</b> 7 KB
Read more📋 Fallon John A. (Ex-Director) plans to sell 14K shares of COLLEGIUM PHARMACEUTICAL, INC (at $35.73 each, total $497K) Filed: Jul 17, 2026 | ID: 005267
Read more📋 Fallon John A. (Ex-Director) plans to sell 8K shares of COLLEGIUM PHARMACEUTICAL, INC (at $36.32 each, total $294K) Filed: Jul 15, 2026 | ID: 005235
Read moreSANTINI GINO 🟡 adjusted position in 0 shares (1 derivative) of COLLEGIUM PHARMACEUTICAL, INC (COLL) at $16.49 Transaction Date: Jun 08, 2026 | Filing ID: 000006
Read moreCollegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read moreNew Form S-8 - COLLEGIUM PHARMACEUTICAL, INC <b>Filed:</b> 2026-06-01 <b>AccNo:</b> 0001104659-26-068987 <b>Size:</b> 197 KB
Read moreNew Form S-8 - COLLEGIUM PHARMACEUTICAL, INC <b>Filed:</b> 2026-06-01 <b>AccNo:</b> 0001104659-26-068985 <b>Size:</b> 350 KB
Read moreFreund John Gordon 🔴 sold 20 shares of COLLEGIUM PHARMACEUTICAL, INC (COLL) at $34.05 Transaction Date: May 18, 2026 | Filing ID: 000004
Read moreLurker Nancy 🟢 acquired 8.7K shares of COLLEGIUM PHARMACEUTICAL, INC (COLL) Transaction Date: May 14, 2026 | Filing ID: 000009
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06431256 | Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Ye… | Phase3 | Attention Deficit Hyperactivity Disorder | Terminated | 2024-09-13 | 2025-07-11 | ClinicalTrials.gov |
| NCT03588806 | Use of Xtampza ER to Overcome Difficulties in Swallowing Opioid Pills | Phase4 | Chronic Pain | Terminated | 2018-05-01 | 2019-10-31 | ClinicalTrials.gov |
| NCT01685684 | Oxycodone DETERx™ Versus Placebo in Chronic Low Back Pain (CLBP) | Phase3 | Chronic Low Back Pain | Completed | 2012-08-01 | 2014-07-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Xtampza ER (oxycodone) | Other | Phase PHASE4 | Chronic Pain | TERMINATED | NCT03588806 |
| Placebo | Other | Phase PHASE3 | Chronic Low Back Pain | COMPLETED | NCT01685684 |
| Oxycodone DETERx | Other | Phase PHASE3 | Chronic Low Back Pain | COMPLETED | NCT01685684 |
| Placebo HLD200 capsules | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder | TERMINATED | NCT06431256 |
| HLD200 methylphenidate hydrochloride capsules | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder | TERMINATED | NCT06431256 |
| Placebo HLD200 capsules | DRUG | Phase PHASE3 | Attention Deficit Hyperactivity Disorder | TERMINATED | NCT06431256 |
| HLD200 methylphenidate hydrochloride capsules | DRUG | Phase PHASE3 | Attention Deficit Hyperactivity Disorder | TERMINATED | NCT06431256 |
| Xtampza ER (oxycodone) | DRUG | Phase PHASE4 | Chronic Pain | TERMINATED | NCT03588806 |
| Placebo | DRUG | Phase PHASE3 | Chronic Low Back Pain | COMPLETED | NCT01685684 |
| Oxycodone DETERx | DRUG | Phase PHASE3 | Chronic Low Back Pain | COMPLETED | NCT01685684 |